Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases

References

• Tool BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4(7):528–539.
   PubMed Web of Science ®Google Scholar
• Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater. 2011;23(12):H41–H56.
   PubMed Web of Science ®Google Scholar
• Hagedorn PH, Hansen BR, Koch T, et al. Managing the sequence-specificity of antisense oligonucleotides in drug discovery. Nucleic Acid Res. 2017;45(5):2262–2282.
   PubMed Web of Science ®Google Scholar
• Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181–202.
   PubMed Web of Science ®Google Scholar
• Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acid Res. 2016;44(14):6518–6548.
   PubMed Web of Science ®Google Scholar
• Zamecnik PC, Stephenson ML. Inhibition of Roas Sarcoma virus replication and cell transformation by a specific oligonucleotide. Proc Natl Acad Sci USA. 1978;75(1):280–284.
   PubMed Web of Science ®Google Scholar
• Havens MA, Hastings ML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acid Res. 2016;44(14):6549–6563.
   PubMed Web of Science ®Google Scholar
• Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35(3):238–248.
   PubMed Web of Science ®Google Scholar
• Boiziau C, Kurfurst R, Cazenave C, et al. Inhibition of translation by antisense oligonucleotides via an RNase-H independent mechanism. Nucleic Acid Res. 1991;19(5):1113–1119.
   PubMed Web of Science ®Google Scholar
• Lennox KA, Behlke MA. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides. Nucleic Acid Res. 2016;44(2):863–877.
   PubMed Web of Science ®Google Scholar
• Hammond SM. An overview of microRNAs. Adv Drug Deliv Rev. 2015;87:3–14.
   PubMed Web of Science ®Google Scholar
• Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov. 2014;13(8):622–638.
   PubMed Web of Science ®Google Scholar
• Gebert LF, Rebhan MA, Crivelli SE, et al. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acid Res. 2014;42(1):609–621.
   PubMed Web of Science ®Google Scholar
• Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811.
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494–498.
   PubMed Web of Science ®Google Scholar
• DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA. 2010;107(19):8800–8805.
   PubMed Web of Science ®Google Scholar
• Kanasty R, Dorkin JR, Vegas A, et al. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967–977.
   PubMed Web of Science ®Google Scholar
• Nimjee SM, White RR, Becker RC, et al. Aptamers as Therapeutics. Annu Rev Rharmacol Toxicol. 2017;57:61–79.
   PubMed Web of Science ®Google Scholar
• Mann MJ. Transcription factor decoys: a new model for disease intervention. Ann New York Acad Sci. 2005;1058:128–139.
   PubMed Web of Science ®Google Scholar
• Kruspe S, Giangrande PH. Aptamer-siRNA chimeras: discovery, progress and future prospects. Biomedicines. 2017;5(3). DOI:10.3390/biomedicines5030045
   PubMed Web of Science ®Google Scholar
• Kreig AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 2012;22(2):77–89.
   PubMed Web of Science ®Google Scholar
• Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol. 1993;39:3–9.
   Google Scholar
• Echigo R, Mochizuki M, Nishimura R, et al. Suppressive effect of hyaluronan on chondrocyte apoptosis in experiment induced acute osteoarthritis in dog. J Vet Med Sci. 2006;68(8):899–902.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Miyauchi S, Nakamura T, et al. The effect of sodium hyaluronate on the growth of rabbit cornea epithelial cells in vitro. J Ocul Pharmacol Ther. 1996;12(4):409–415.
   PubMed Web of Science ®Google Scholar
• Frenkel JS. The role of hyaluronan in wound healing. Int Wound J. 2014;11(2):159–163.
   PubMed Web of Science ®Google Scholar
• Dechert TA, Ducale AE, Ward SI, et al. Hyaluronan in human acute and chronic dermal wounds. Wound Repair Regener. 2006;14(3):252–258.
   PubMed Web of Science ®Google Scholar
• Leach JB, Schmidt CE. Hyaluronan. Encyclopedia of biomaterials and biomedical engineering. New York (NY): Marcel Dekker; 2004. p. 779–789.
   Google Scholar
• Toole BP, Ghatak S, Misra S. Hyaluronan oligosaccharides as a potential anticancer therapeutic. Curr Pharm Biotechnol. 2008;9(4):249–252.
   PubMed Web of Science ®Google Scholar
• Stern R, Kogan MJ, Jedrzejas MJ, et al. The many ways to cleave hyaluronan. Biotechnol Adv. 2007;25(6):537–557.
   PubMed Web of Science ®Google Scholar
• Stern R. Hyaluronan catabolism: a new metabolic pathway. Eur J Cell Biol. 2004;83(7):317–325.
   PubMed Web of Science ®Google Scholar
• Cui X, Xu H, Zhou S, et al. Evaluation of angiogenic activities of hyaluronan oligosaccharides of defined minimum size. Life Sci. 2009;85(15–16):573–577.
   PubMed Web of Science ®Google Scholar
• Menzel EJ, Farr C. Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Cancer Lett. 1998;131(1):3–11.
   PubMed Web of Science ®Google Scholar
• Oh EJ, Park K, Kim KS, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release. 2010;141(1):2–12.
   PubMed Web of Science ®Google Scholar
• Bradbury J. A therapeutic future for CD44 in inflammation? Lancet. 2002;359(9322):2008.
   PubMed Web of Science ®Google Scholar
• Banerji S, Ni J, Wang SX, et al. LIVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol. 1999;144(4):789–801.
   PubMed Web of Science ®Google Scholar
• Zhou B, Oka JA, Singh A, et al. Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE). J Biol Chem. 2007;282(5):2785–2797.
   PubMed Web of Science ®Google Scholar
• Christner JE, Brown ML, Dziewiatkowski DD. Interaction of cartilage proteoglycans with hyaluronic acid. The role of the hyaluronic acid carboxyl groups. Biochem J. 1977;167(3):711–716.
   PubMed Web of Science ®Google Scholar
• Graça A, Gonçalves LM, Raposo S, et al. Useful in vitro tyechniques to evaluate the mucoadhesive properties of hyaluronic acid-based ocular delivery systems. Pharmaceutics. 2018;10(3):110.
   PubMed Web of Science ®Google Scholar
• Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta. 1999;1462(1–2):55–70.
   PubMed Web of Science ®Google Scholar
• Park K, Yang J-A, Lee M-Y, et al. Reducible hyaluronic acid−siRNA Conjugate for target specific gene silencing. Bioconjug Chem. 2013;24(7):1201–1209.
   PubMed Web of Science ®Google Scholar
• Jang YL, Ku SH, So JL, et al. Hyaluronic acid−siRNA conjugate/reducible polyethyleneimine complexes for targeted siRNA delivery. J Nanosci Nanotechnol. 2014;14(10):7388–7394.
   PubMed Web of Science ®Google Scholar
• Kim S-Y, Heo MB, Hwang G-S, et al. Multivalent polymer nanocomplex targeting endosomal receptor of immune cells for enhanced antitumor and systemic memory response. Angew Chem Int Ed. 2015;54(28):8139–8143.
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5(6):471–484.
   PubMed Web of Science ®Google Scholar
• Lee H, Mok H, Lee S, et al. Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release. 2007;119(2):245–252.
   PubMed Web of Science ®Google Scholar
• Han S-E, Kang H, Shim GY, et al. Cationic derivatives of biocompatible hyaluronic acids delivery of siRNA and antisense oligonucleotides. J Drug Target. 2009;17(2):123–132.
   PubMed Web of Science ®Google Scholar
• Jiang G, Park K, Kim J, et al. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis. Mol Pharm. 2009;6(3):727–737.
   PubMed Web of Science ®Google Scholar
• Park K, Hong SW, Hur W, et al. Target specific systemic delivery of TGF-β siRNA/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis. Biomaterials. 2011;32(21):4951–4958.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Iyer AK, Morrissey DV, et al. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials. 2013;34(13):3489–3502.
   PubMed Web of Science ®Google Scholar
• Tripathi SK, Gupta S, Gupta KC, et al. Efficient DNA and siRNA delivery with biodegradable cationic hyaluronic acid conjugates. RSC Adv. 2013;3(36):15687–15697.
   Web of Science ®Google Scholar
• Yang X, Iyer AK, Singh A, et al. Claster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer. Pharm Res. 2015;32(6):2097–2109.
   PubMed Web of Science ®Google Scholar
• Parayath NN, Parikh A, Amiji MM. Repolarization of tumor-associated macrophages in a genetically engineered nonsmall cell lung cancer model by intraperitoneal administration of hyaluronic acid-based nanoparticles encapsulating microRNA-125b. Nano Lett. 2018;18(6):3571–3579.
   PubMed Web of Science ®Google Scholar
• Park K, Lee M-Y, Kim KS, et al. Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate. Biomaterials. 2010;31(19):5258–5265.
   PubMed Web of Science ®Google Scholar
• Forrest ML, Koerber JT, Pack DW. A degradable polyethyleneimine derivative with low toxicity for highly efficient gene delivery. Bioconjug Chem. 2003;14(5):934–940.
   PubMed Web of Science ®Google Scholar
• Shen Y, Li Q, Tu J, et al. Synthesis and characterization of low molecular weight hyaluronic acid-based cationic micelles for efficient siRNA delivery. Carbohydr Polym. 2009;77(1):95–104.
   Web of Science ®Google Scholar
• Shen Y, Wang B, Lu Y, et al. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery. Int J Pharm. 2011;414(1–2):233–243.
   PubMedGoogle Scholar
• Heo R, Yoon HY, Ko H, et al. Gold-installed biostable nanocomplexes for tumor-targeted siRNA delivery in vivo. Chem Commun. 2015;51(93):16656–16659.
   PubMed Web of Science ®Google Scholar
• Tai L, Liu C, Jiang K, et al. A novel penetratin-modified complex for noninvasive intraocular delivery of antisense oligonucleotides. Int J Pharm. 2017;529(1–2):347–356.
   PubMed Web of Science ®Google Scholar
• Yang Y, Jia Y, Xiao Y, et al. Tumor-targeting anti-microRNA-155 delivery based on biodegradable poly(ester amine) and hyaluronic acid shielding for lung cancer therapy. ChemPhysChem. 2018;19(16):2058–2069.
   PubMed Web of Science ®Google Scholar
• Zhao Y, He Z, Gao H, et al. Fine tuning of core-shell structure of hyaluronic acid/cell-penetrating peptides/siRNA nanoparticles for enhanced gene delivery to macrophages in antiatherosclerotic therapy. Biomacromolecules. 2018;19(7):2944–2956.
   PubMed Web of Science ®Google Scholar
• Kim E-J, Shim G, Kim K, et al. Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs. J Gene Med. 2009;11(9):791–803.
   PubMed Web of Science ®Google Scholar
• Choi K, Jang M, Kim JH, et al. Tumor-specific delivery of siRNA using supramolecular assembly of hyaluronic acid nanoparticles and 2b RNA-binding protein/siRNA complexes. Biomaterials. 2014;35(25):7121–7132.
   PubMed Web of Science ®Google Scholar
• Chen HY, Yang J, Lin C, et al. Structural basis for RNA-silencing suppression by tomato aspermy virus protein 2b. EMBO Rep. 2008;9(8):754–760.
   PubMed Web of Science ®Google Scholar
• Choi KY, Silvestre OF, Huang X, et al. A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo. Nat Protoc. 2014;9(8):1900–1915.
   PubMed Web of Science ®Google Scholar
• Choi KY, Silvestre OF, Huang X, et al. Versatile RNA interference nanoplatform for systemic delivery of RNAs. ACS Nano. 2014;8(5):4559–4570.
   PubMed Web of Science ®Google Scholar
• Forti E, Kryukov O, Elovic E, et al. A bridge to silencing: co-assembling anionic nanoparticles of siRNA and hyaluronan sulfate via calcium ion bridges. J Control Release. 2016;232:215–227.
   PubMed Web of Science ®Google Scholar
• Ran R, Liu Y, Gao H, et al. PEGylated hyaluronic acid-modified liposomal delivery system with anti-γ-glutamylcuclotransferase siRNA for drug-resistant MCF-7 breast cancer therapy. J Pharm Sci. 2015;104(2):476–484.
   PubMed Web of Science ®Google Scholar
• Sun Q, Kang Z, Xue L, et al. A collaborative assembly strategy for tumor-targeted siRNA delivery. J Am Chem Soc. 2015;137(18):6000–6010.
   PubMed Web of Science ®Google Scholar
• Nascimento TL, Hillaireau H, Vergnaud J, et al. Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model. Int J Pharm. 2016;514(1):103–111.
   PubMedGoogle Scholar
• Nascimento TL, Hillaireau H, Noiray M, et al. Supramolecular organization and siRNA binding of hyaluronic acid-coated lipoplexes for targeted delivery to the CD44 receptor. Langmuir. 2015;31(41):11186–11194.
   PubMed Web of Science ®Google Scholar
• Shen Y, Wang J, Li Y, et al. Co-delivery of siRNA and paclitaxel into cancer cells by hyaluronic acid modified redox-sensitive disulfide-cross-linked PLGA-PEI nanoparticles. RSC Adv. 2015;5(58):46464–46479.
   Web of Science ®Google Scholar
• Wang Y, Zhao Q, Han N, et al. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomed Nanotechnol Biol Med. 2015;11(2):313–327.
   PubMed Web of Science ®Google Scholar
• Chen Z, Li Z, Lin Y, et al. Bioresponsive hyaluronic acid-capped mesoporous silica nanoparticles for targeted drug delivery. Chem Eur J. 2013;19(5):1778–1783.
   PubMed Web of Science ®Google Scholar
• Shahin SA, Wang R, Simargi SI, et al. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomed Nanotechnol Biol Med. 2018;14(4):1381–1394.
   PubMed Web of Science ®Google Scholar
• Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology. 1973;52(2):456–467.
   PubMed Web of Science ®Google Scholar
• Lee MS, Lee JE, Byun E, et al. Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate. J Control Release. 2014;192:122–130.
   PubMed Web of Science ®Google Scholar
• Qiu C, Wei W, Sun J, et al. Systemic delivery of siRNA by hyaluronan-functionalized calcium phosphate nanoparticles for tumor-targeted therapy. Nanoscale. 2016;8(26):13033–13044.
   PubMed Web of Science ®Google Scholar
• Hou C, Bai H, Wang Z, et al. A hyaluronan-based nanosystem enables combined anti-inflammation of mTOR gene silencing and pharmacotherapy. Carbohydr Polym. 2018;195:339–348.
   PubMed Web of Science ®Google Scholar
• Shi K, Fang Y, Gao S, et al. Inorganic kernel – supported asymmetric hybrid vesicles for targeting delivery of STAT3-decoy oligonucleotides to overcome anti-HER2 therapeutic resistance of BT474R. J Control Release. 2018;279:53–68.
   PubMed Web of Science ®Google Scholar
• Jadhav S, Käkelä Y, Mäkilä J, et al. Synthesis and in vivo PET imaging of hyaluronan conjugates of oligonucleotides. Bioconjug Chem. 2016;27(2):391–403.
   PubMed Web of Science ®Google Scholar
• Jonnalagadda S, Smith C, Mhango H, et al. The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer. Chest. 2011;140(2):433–440.
   PubMed Web of Science ®Google Scholar
• Boussif O, Lezoualc’h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA. 1995;92(16):7297–7301.
   PubMed Web of Science ®Google Scholar
• Guo S, Huang L. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. J Nanomater. 2011;2011:1–12.
   PubMed Web of Science ®Google Scholar
• Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007;83(3):185–194.
   Google Scholar
• Ossipov DA. Nanostructured hyaluronic acid based materials for active delivery to cancer. Expert Opin Drug Deliv. 2010;7(6):681–703.
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17):11393–11398.
   PubMed Web of Science ®Google Scholar
• Kageyama S, Iwaki H, Inoue H, et al. A novel tumor-related protein, C7orf24, identified by proteome differential display of bladder urothelial carcinoma. Proteomics Clin Appl. 2007;1(2):192–199.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22(53):8581–8589.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Abubaker K, Findlay J, et al. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Target. 2010;10(3):268–278.
   PubMed Web of Science ®Google Scholar
• Da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Ann Rev Pathol. 2011;6:49–69.
   PubMed Web of Science ®Google Scholar
• Sandhu SK, Volinia S, Costinean S, et al. miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model. Proc Natl Acad Sci USA. 2012;109(49):20047–20052.
   PubMed Web of Science ®Google Scholar
• Furtek SL, Backos DS, Matheson CJ, et al. Strategies and approaches of targeting STAT3 for cancer treatment. ACS Chem Biol. 2016;11(2):308–318.
   PubMed Web of Science ®Google Scholar
• Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer. 2013;13(9):663–673.
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. New Engl J Med. 2015;372(8):724–734.
   PubMed Web of Science ®Google Scholar
• de la Rosa JMR, Tirella A, Gennari A, et al. The CD44-mediated uptake of hyaluronic acid-based carriers in macrophages. Adv Healthcare Mater. 2017;6(4):1601012.
   Web of Science ®Google Scholar
• Kim KS, Hur W, Park SJ, et al. Bioimaging for targeted delivery of hyaluronic acid derivatives to the livers in cirrhotic mice using quantum dots. ACS Nano. 2010;4(6):3005–3014.
   PubMed Web of Science ®Google Scholar
• Soutschek J, Akins A, Bramlage B, et al. Therapeutic silencing of endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173–178.
   PubMed Web of Science ®Google Scholar
• Breitkopf K, Haas S, Wiercinska E, et al. Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res. 2005;29(11Suppl):121S–131S.
   PubMedGoogle Scholar
• Abrams MT, Koser ML, Seitzer J, et al. Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle: effect of dexamethasone co-treatment. Mol Ther. 2010;18(1):171–180.
   PubMed Web of Science ®Google Scholar
• Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature. 2011;469(7330):323–335.
   PubMed Web of Science ®Google Scholar
• Hu Y, Liu J, Wu YF, et al. mTOR and autophagy in regulation of acute lung injury: a review and perspective. Microbes Infect. 2014;19(9):727–734.
   Google Scholar
• Lee GY, Kim JH, Choi KY, et al. Hyaluronic Acid Nanoparticles for Active targeting Atherosclerosis. Biomaterials. 2015;53:341–348.
   PubMed Web of Science ®Google Scholar
• Moore KJ, Sheedy FJ, Fisher EA. Macrophages in Atherosclerosis: a Dynamic Balance. Nat Rev Immunol. 2013;13(10):709–721.
   PubMed Web of Science ®Google Scholar
• Kzhyshkowska J, Neyen C, Gordon S. Role of macrophage scavenger receptors in atherosclerosis. Immunobiology. 2012;217(5):492–502.
   PubMed Web of Science ®Google Scholar
• Kume M, Kita T. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) in atherosclerosis. Trends Cardiovasc Med. 2001;11(1):22–25.
   PubMed Web of Science ®Google Scholar
• Campbell JP, McFarland TJ, Stout JT. Ocular gene therapy. Dev Ophthalmol. 2016;55:317–321.
   PubMedGoogle Scholar